Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab and Anlotinib in Advanced Ovarian Clear Cell Carcinoma
NCT05600998Phase 2Unknown
- Sponsor
- Peking University Third Hospital
- Start
- Oct 2022
- Primary completion
- Sep 2023
- Modality
- Immune Checkpoint Inhibitors
01
Overview
A Phase 2 trial of camrelizumab in ovarian clear cell carcinoma (OCCC), sponsored by Peking University Third Hospital. Status: unknown.
02
Drugs
camrelizumab
03
Conditions
ovarian clear cell carcinoma (OCCC)
Beyond the preview
Go deeper on NCT05600998.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05600998.